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Abstract
To protect against dengue viral infection, a novel lipidated dengue subunit vaccine was rationally designed to contain the
consensus amino acid sequences derived from four serotypes of dengue viruses. We found that the lipidated consensus
dengue virus envelope protein domain III (LcED III) is capable of activating antigen-presenting cells and enhancing cellular
and humoral immune responses. A single-dose of LcED III immunization in mice without extra adjuvant formulation is
sufficient to elicit neutralizing antibodies against all four serotypes of dengue viruses. In addition, strong memory responses
were elicited in mice immunized with a single-dose of LcED III. Quick, anamnestic neutralizing antibody responses to a live
dengue virus challenge were elicited at week 28 post-immunization. These results demonstrate the promising possibility of
a future successful tetravalent vaccine against dengue viral infections that utilizes one-dose vaccination with LcED III.
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Introduction
The dengue viruses (DV) are members of the Flavivirus genus of
the Flaviviridae family. There are four antigenically different
serotypes (DV-1 through DV-4) of DV [1]. Each of the four
serotypes of dengue viral infection is able to cause dengue fever,
which is generally a self-limited febrile illness. However, certain
dengue-infected individuals develop the life-threatening dengue
hemorrhagic fever (DHF) or dengue shock syndrome (DSS) [2,3].
The pathogeneses of DHF and DSS are complicated and still not
fully understood. It is generally accepted that an effective dengue
vaccine must provide concrete and long-lasting cross-protection
against all four serotypes of DV.
In the past several decades, enormous efforts have been put into
the development of dengue vaccines to combat the disease [4,5].
These efforts include vaccines utilizing live attenuated strains of all
four dengue viral serotypes [6–9], inactivated whole virions
[10,11], chimeric or genetically engineered strains [12–15], virally
vectors [16–18], naked DNA [19–21], and recombinant subunits
[10,22–26]. Although some level of success has been attained,
several obvious obstacles still exist. For example, live attenuated
dengue vaccines must elicit appropriately balanced tetravalent
immunity, and they must be characterized by a good safety profile.
The inactivated whole virion dengue vaccines were restricted by
the low virus yields in typical dengue viral cultures. Presently, no
licensed dengue vaccine is available.
Recombinant subunit dengue vaccines may provide significant
benefits over other approaches. For instance, subunit vaccines
eliminate exposure to the virus, which means they are safer, and
they are more easily manipulated through dose adjustments to
obtain a balanced immune response to all four serotypes of DV.
However, subunit vaccines are recognized as poor immunogens,
they require several immunizations and they must be formulated
with a strong adjuvant to generate a sufficient immune response
[10,22–29].
The crystal structure of the envelope protein from DV revealed
that it contains three distinct domains [30–32]. Domain III of the
dengue envelope protein has been associated with receptor
binding [33,34], and it contains several neutralizing epitopes
[35–40]. These results suggest that domain III of the dengue virus
envelope protein is a promising subunit vaccine candidate. In our
previous study [25], we described the development of a novel
subunit dengue vaccine candidate comprising a consensus dengue
virus envelope protein domain III (cED III). Mice immunized with
recombinant cED III formulated with aluminum phosphate were
able to elicit neutralizing antibodies against the four serotypes of
dengue virus.
To avoid the inherent problems of subunit dengue vaccines (poor
immunogenicity, requirement of adjuvant, and multiple immuniza-
tions), we established a novel platform technology that can express
high levels of recombinant lipoproteins with intrinsic adjuvant
properties [41]. In this study, we demonstrated that lipidated cED
III (LcED III) was able to induce neutralizing antibodies against all
serotypesof DVwithout theuse ofexogenous adjuvant. Moreover, a
single dose of LcED III was capable of inducing strong neutralizing
antibody memory responses.
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LcED III activates macrophages and up-regulate CD40,
MHC II, and costiumlatory molecules expression
Lipoproteins or lipopeptides have been shown to activate
antigen-presenting cells by triggering toll-like receptors [42–45].
To analyze the functional activity of LcED III, RAW 264.7
macrophage cells were stimulated with cED III or LcED III at
10 mg/mL for 16 hours. The expression levels of CD40, CD80,
CD86, or MHC II on RAW 264.7 macrophage cells were analyzed
by flow cytometry. As shown in Fig. 1A, LcED III up-regulated the
expression of CD40, CD80,CD86, and MHCII,while cEDIII was
ineffective at up-regulating these molecules. The mean fluorescence
intensities (MFIs) obtained from cells cultured in medium alone
were used to determine basal expression levels and were defined as
1. The relative MFIs from three independent experiments are
summarized in Fig. 1B. LcED III stimulated macrophages to up-
regulate CD40, CD80, CD86, and MHC II expression at levels 4-
to 16-fold higher compared to those stimulated by cED III or
medium alone.
LcED III enhances T- and B-cell immune responses
Because recombinant LcED III up-regulated the expression of
CD40, MHC II, and costimulatory molecules on macrophages in
vitro, we evaluated the immune responses elicited by LcED III.
Groups of BALB/c mice were immunized with cED III or LcED
III two times at a two-week interval. Animals immunized with PBS
alone served as negative controls. One week after the last immu-
nization, splenocytes were examined for proliferative capacity and
secretion of IFN-c in response to cED III stimulation for 4 days.
Fig. 2A shows that mice immunized with cED III did not develop
a notable antigen-specific proliferative response. The stimulation
index (SI) of the cells from these mice was comparable to the SI
obtained from the splenocytes derived from mice immunized with
PBS. In contrast, significant T-cell proliferation was elicited in
mice immunized with LcED III. Moreover, the splenocytes
obtained from LcED III-immunized mice contained a substantial
number of IFN-c-producing spots, which were significantly more
numerous than in the splencoytes obtained from cED III- or PBS-
immunized mice (Fig. 2B).
Next, we examined the IgG antibody responses following two
doses (20 mg per dose) of cED III or LcED III vaccination. Serum
samples were collected from the immunized mice at different time
points, as indicated in Fig. 2C. Negligible levels of anti-cED III
IgG antibodies were detected in mice immunized with cED III
alone. However, mice immunized with LcED III were able to
generate anti-cED III IgG antibodies. Importantly, substantial
levels of anti-cED III IgG antibodies were maintained for over 24
weeks after the priming.
As the preceding experiments show that the LcED III can
induce stronger antibody responses than cED III. The question to
be raised at this point, will these antibodies recognize the four
serotypes of dengue viruses? To address this, we performed in-
direct immunofluorescence staining to analyze the antibodies in
sera of mice immunized with LcED III. As shown in Fig. 3, pre-
immuneserum didnot produce immunofluorescencereactivitywith
any of the four dengue viruses. However, immune sera recognized
all four dengue viruses as evidenced by immunofluorescence spectra
(Fig. 3). These results suggest that antibodies induced by vaccination
with LcED III can react with all four dengue viruses.
LcED III elicits cross-neutralizing antibodies and memory
immunity
The major objective of this study was to explore whether LcED
III could induce cross-neutralizing antibody responses. To analyze
the neutralizing ability against the 4 serotypes of DV induced by
Figure 1. Effects of LcED III on the activation of RAW 264.7 macrophage cells. (A) RAW 264.7 macrophage cells were cultured either in
media alone or in media supplemented with cED III or LcED III at 10 mg/mL. After incubation for 16 hours, the surface markers CD40, CD80, CD86, and
MHC II were analyzed using flow cytometry. A representative experiment is shown. (B) The mean fluorescence intensity (MFI) for cells cultured in
media alone was defined as the basal expression level. Relative MFIs were plotted. The means and standard deviations (SD) from three independent
experiments are shown.
doi:10.1371/journal.pone.0023319.g001
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III or LcED III were collected and determined the neutralizing
antibody titers by focus reduction neutralization tests (FRNT). As
shown in Fig. 4A, neutralizing antibody activities were not detected
in mice immunized with cED III. Remarkably, antisera obtained
from LcED III immunized mice were capable of blocking all 4
serotypes of dengue viral infection in vitro. The geometric mean
neutralizing antibody titers against dengue-1, dengue-2, dengue-3,




2.8, respectively. These re-
sults indicate that LcED III alone is able to induce neutralizing
antibodies that can concurrently inhibit dengue-1, dengue-2,
dengue-3, and dengue-4 viral infection.
To test the durability of neutralizing antibody responses, mice
were injected intraperitoneally with 5610
6 focus-forming units
(FFU) of live dengue-2 virus at week 28 after the first immunization.




3.6 neutralizing antibody titers at
5, 15, and 21 days post-viral challenge, respectively. These
neutralizing capacities were equivalent to the sera from naı ¨ve mice
challenged with live DV. Notably, we observed over a 16-fold
increase inthe levelsofneutralizing antibodiesagainst dengue-2 at 5
days post-viral challenge. The neutralizing antibody titers were
found to be .2
6 at all time points (5, 15, and 21 days post-viral
challenge) examined (Fig. 4B). These results provide tangible evi-
dence that an efficient anamnestic neutralizing antibody response is
induced in mice vaccinated with LcED III.
A single dose of LcED III is able to induce anamnestic
neutralizing antibody responses
To evaluate the potency of LcED III, groups of BALB/c mice
were immunized with a single-dose vaccine containing various
amounts (20, 5, or 1 mg) of LcED III. The sera from immunized
mice were analyzed for the presence of cED III-specific antibodies
or neutralizing capacity. The time course of seroconversion rates
are shown in Fig. 5A. A seropositive sample is defined as when the
optical density of the sample at a 100-fold dilution is more than
two times higher than that of pre-immune serum. Only 60–80% of
the mice vaccinated with 1 mg of LcED III were seropositive.
Interestingly, the mice that received either 5 or 20 mg of LcED III
generated high levels of anti-cED III IgG antibodies. All animals
were seroconverted, and their antibodies endured over 20 weeks.
Fig. 5B shows the time course of optical density obtained from the
reactivity of serum samples with cED III at a 2500-fold dilution
after the immunization. In summary, the mice that received 1 mg
of LcED III generated low levels of anti-cED III IgG antibodies.
Significant antibody responses were generated in mice immunized
with either 20 or 5 mg of LcED III.
The serum samples were collected at week 4, and the neu-
tralizing capacity against the 4 serotypes of dengue virus was
examined. As shown in Fig. 5C, no significant levels of neutralizing
antibodies were detected in the sera obtained from mice
immunized with 1 mg of LcED III. Remarkably, mice immunized
with a single dose of 20 mg of LcED III were able to generate
cross-neutralizing antibodies against the 4 serotypes of DV.
To evaluate the memory neutralizing antibody responses, mice
were injected intraperitoneally with 5610
6 FFU of live dengue-2
virus at week 28 after the immunization. No neutralizing antibody
activity was detected in the sera obtained from naı ¨ve mice until 19
days after viral challenge (Fig. 5D). In contrast, geometric mean
neutralizing antibody titers were detected and maintained at 2
3.8–
2
4.8 in mice immunized with 1 mg of LcED III at all times that we
examined. Moreover, mice immunized with 20 and 5 mg of LcED
III were found to have quicker and stronger neutralizing antibody
responses. The geometric mean neutralizing antibody titers of
these two groups were determined to be 2
6 and 2
5.4 on the 4th day
post-viral challenge, respectively. The geometric mean neutraliz-
ing antibody titers in the sera obtained from mice immunized with
20 and 5 mg LcED III both further increased to 2
7 on the 12th day
after viral challenge. These results indicate that a single dose of
LcED III is able to induce a memory neutralizing antibody
response.
Discussion
The dengue viral envelope protein is responsible for viral
attachment by binding to the cellular receptor. Domain III of the
Figure 2. LcED III augments cellular and humoral immune responses. BALB/c mice were immunized subcutaneously with 20 mg of cED III or
LcED III two times at a two-week interval. (A) Seven days after the last immunization, splenocytes were incubated with or without cED III (10 mg/mL).
The stimulation index (SI) is defined as the ratio of the mean counts per minute (cpm) with cED III stimulation to the mean cpm without antigen
stimulation. Results were pooled from two independent experiments. P values were calculated using an unpaired one-tailed Student’s t-test. (B) The
frequencies of IFN-c-secreting cells in spleens were evaluated by mouse IFN-c ELISPOT kits. Results are representative of two independent
experiments. P values were calculated using the unpaired one-tailed Student’s t-test. (C) Sera were collected at the indicated time points after the first
immunization. Serum samples were diluted 1:500 and 1:2500 in PBS. Antibody responses against cED III were evaluated by ELISA. Pre-immune sera
(week 0) were collected and used as basal levels. Results are plotted as the mean of optical density values plus standard deviation (n=5).
doi:10.1371/journal.pone.0023319.g002
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[33,34]. It has been demonstrated that envelope protein domain
III is a leading target in dengue subunit vaccine development [46].
In our previous study [25], we designed a consensus amino acid
sequence of domain III from the dengue envelope protein, and we
used it successfully for dengue subunit vaccine development.
Unfortunately, the cED III vaccine contained a problem inherent
to subunit vaccines, poor immunogenicity. Without the addition of
proper adjuvant, cED III alone induced low neutralizing antibody
responses. To overcome this inherent problem of subunit vaccines,
we developed LcED III as a novel dengue vaccine candidate that
has a built-in intrinsic adjuvant. In this study, we demonstrated
that LcED III stimulated macrophages and up-regulated the
expression of CD40, MHC II, and costimulatory molecules in vitro
(Fig. 1). These results are consistent with our previous findings in
the bone marrow-derived dendritic cells [41,42]. We then
evaluated the capacity of LcED III to elicit cellular and humoral
immune responses. As expected, LcED III is superior to cED III in
its ability to induce cED III-specific T-cell proliferative responses,
IFN-c secretion, and IgG production (Fig. 2). Taken together, the
results demonstrate that LcED III is able to activate antigen-
presenting cells and enhance cellular and humoral immune
responses.
After verifying that LcED III stimulates superior immune
responses, we initiated experiments to study the capability of LcED
III of inducing neutralizing antibodies against the 4 serotypes DV.
LcED III alone, without exogenous adjuvant formulation, was able
toinducecross-neutralizing antibodyresponses(Fig.4A). Moreover,
the neutralizing antibodies were evoked rapidly when the
immunized mice were challenged with live DV (Fig. 4B). These
results suggest that memory neutralizing antibody responses were
elicited in mice immunized with LcED III.
It has been demonstrated that envelope protein domain III is a
suitable candidate for a dengue subunit vaccine [46]. However,
several vaccination doses and a proper adjuvant are required to
obtain an effective immunity [22,25–29]. The multiple doses
usually result in an increase in vaccination cost, thus, a single-dose
vaccine is more cost-effective than a multiple-dose vaccine. Our
vaccine candidate, LcED III, is highly immunogenic (Fig. 5A and
5B). We demonstrated that a single dose, particularly without
exogenous adjuvant formulation, is sufficient to stimulate neutral-
izing antibody responses (Fig. 5C). Importantly, the neutralizing
antibodies were durable, and they could be recalled quickly. As
shown in Fig. 5D, neutralizing antibodies were detected 4 days
after viral challenge in the groups of mice immunized with a single
dose of 1, 5, and 20 mg of LcED III, but they were not detectable
in naı ¨ve mice challenged with the same titer of DV.
Although low cross-neutralizing antibody titers were induced by
LcED III (Fig. 4A and 5C), substantial anamnestic neutralizing
antibody responses were obtained in LcED III-immunized mice
(Fig. 4B and 5D). In summary,we evaluatedthe novel LcED III as a
potential dengue vaccine candidate. Overall, our results provide a
new window of opportunity for dengue subunit vaccines, particu-
larly for those based on dengue envelope protein domain III.
Materials and Methods
Ethics statement
All animal studies were approved by the Animal Committee of
the National Health Research Institutes (Protocol No: NHRI-
IACUC-095001) and were performed according to their guide-
lines.
Figure 3. Antibodies induced by immunization with LcED III recognize all four dengue viruses. K562 cells were infected with each of the
four dengue viruses as indicated. Three days after infection, the virus-infected cells were fixed and probed with either sera drawn before (Pre-imm) or
after (Imm) immunizaiton with LcED III. Cellular DNA was visualized by Hoechst stains. The virus-infected cells were indicated by arrows. The right
panels show the close-up images of merging Hoechst and FITC stains of the marked areas.
doi:10.1371/journal.pone.0023319.g003
Figure 4. Induction of cross-neutralizing antibodies and
memory neutralizing antibodies by vaccination with LcED III.
BALB/c mice (n=5) were immunized subcutaneously with 20 mg of cED III
or LcED III two times at a two-week interval. (A) Sera samples were
collected twoweeksafter the last immunization. (B) Immunized micewere
inoculated intraperitoneally with 5610
6 FFU oflive dengue-2 virus at week
28 post-priming. Sera obtained from naı ¨ve mice inoculated with live
dengue-2 virus served as controls. Serum samples were collected from
each mouse to evaluate neutralization of the infectivity of dengue virus by
FRNT.Theneutralizingantibodytiterwascalculatedasthereciprocalofthe
highest dilution that resulted in a 40% reduction of FFU compared to that
of a control that consisted of treatment with virus and pre-immunization
sera. Values are representative of two independent experiments.
doi:10.1371/journal.pone.0023319.g004
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LcED III
Preparation of cED III and LcED III were performed as
previously described [25,41]. Briefly, the cED III gene, either
alone or fused with a lipidation signal DNA sequence, was cloned
into the pET-22b(+) vector and expressed in E. coli BL21 (DE3) or
C43 (DE3), respectively. Recombinant cED III and LcED III were
purified by immobilized metal affinity chromatography, and the
amount of residual LPS was negligible (,3 EU/mg) in both
preparations.
Virus
Four serotypes of the DV, namely, dengue-1/Hawaii, dengue-2/
PL046, dengue-3/H-087, and dengue-4/H241, were used for this
study. Virus propagation was performed in C6/36 cells, and virus
titers were determined by focus-forming assays with BHK-21 cells.
Mouse experiments
Five BALB/c mice (6–8 weeks of age) were immunized
subcutaneously with cED III or LcED III (1–20 mg per dose).
Mice were given one or two immunizations at a two-week interval
with the same regimen. To detect the anamnestic response gen-
erated by immunization, immunized mice were inoculated
intraperitoneally with 5610
6 FFU of live dengue-2 virus. Blood
was collected from each mouse at different time points, as indicated.
Sera were prepared and stored at 280uC until use.
Lymphocyte proliferation assays
To determine whether cED III-specific lymphoproliferative
responses were induced in immunized animals, spleens were
removed one week after the last immunization to make single-cell
suspensions. Splenocytes were seeded at a concentration of 2610
5
cells / well in 96-well plates and stimulated with cED III (10 mg/
Figure 5. A single-dose of LcED III is able to induce cross-neutralizing antibodies and memory neutralizing antibodies. BALB/c mice
(n=5) were immunized once subcutaneously with 1, 5, or 20 mg of LcED III. (A) Seroconversion rates and (B) the optical density of serum samples at a
2500-fold dilution versus time after immunization are plotted. (C) Sera samples were collected four weeks after the immunization. The neutralizing
antibodytiteroftheseraineachmousewasdeterminedbyFRNT.(D)Immunizedmicewerechallengedintraperitoneallywith5610
6 FFUoflivedengue-2
virus at week 28 post-priming. Sera obtained from naı ¨ve mice inoculated with live dengue-2 virus served as controls. Serum samples were collected in
each mouse to evaluate neutralization of the infectivity of dengue virus by FRNT. The neutralizing antibody titer was calculated as the reciprocal of the
highest dilution that resulted in a 40% reduction of FFU compared to that of a control that consisted of treatment with virus and pre-immunization sera.
doi:10.1371/journal.pone.0023319.g005
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the final 18 hours of culture, 1 mCi of [
3H]-thymidine was added
to each well, and the cells were harvested using a FilterMate
automatic cell harvester (Packard). The incorporated radioactivity
was determined with a TopCount microplate scintillation counter
(Packard). Con A (5 mg/mL) was included in the assay as a positive
control. The induced stimulation index is defined as the ratio of
the mean counts per minute (cpm) with cED III stimulation to the
mean cpm without cED III stimulation.
ELISPOT assays
The number of IFN-c-producing cells was determined by
mouse IFN-c ELISPOT kits (eBioscience). All the assays were
performed according to the procedures that were specified in the
instructions included in the kits. Briefly, 96-well plates with PVDF
membranes (Millipore) were coated with capture antibody and
incubated at 4uC for 18 hours. The plates were washed twice and
blocked with RPMI medium supplemented with fetal bovine
serum (10%) for one hour to prevent nonspecific binding in later
steps. Splenocytes were seeded at a concentration of 5610
5 cells /
well and stimulated with cED III (10 mg/mL) for 4 days at 37uCi n
a5 %C O 2 humidified incubator. After incubation, the cells were
removed from the plates by washing three times with 0.05% (w/v)
Tween 20 in PBS. A 100 mL aliquot of biotinylated detection
antibody was added to each well. The plates were incubated at
37uC for 2 hours. The washing steps were repeated as above, and
after a 45-minute incubation at room temperature with the avidin-
horseradish peroxidase complex reagent, the plates were washed
three times with 0.05% (w/v) Tween 20 in PBS and then three
times with PBS alone. A 100 mL aliquot of 3-amine-9-ethyl
carbazole (Sigma-Aldrich) staining solution was added to each well
to develop the spots. The reaction was stopped after one hour by
placing the plates under tap water. The spots were counted using
an ELISPOT reader (Cellular Technology Ltd.).
Measurement of antibody responses
The levels of anti-cED III IgG in the serum samples was
determined by titrating the samples as previously described [25].
Briefly, purified cED III was coated on 96-well plates. Bound IgG
was detected with horseradish peroxidase-conjugated goat anti-
mouse IgG Fc. After the addition of 3, 39,5 ,5 9-tetramethylbenzi-
dine (TMB), the absorbance was measured with an ELISA reader
at 450 nm.
Immunofluorescence assay
K562 cells were infected respectively with each of the four
dengue virus serotypes. Three days after infection, viruses in the
infected cells were detected by an indirect immunofluorescence
assay, using mouse pre-immune and immune sera (from LcED III-
immunized mice). Cellular DNA was labeled by Hoechst stains.
Focus reduction neutralization tests (FRNT)
Antibody-mediated DV neutralization in BHK-21 cells was
determined by FRNT as previously described [25]. Briefly, a
monolayer of BHK-21 cells in 24-well plates was inoculated with
DV that had been pre-mixed with pre-immunization or post-
immunization sera to a final volume of 0.5 mL. The virus titer
prior to pre-mixing was about 50 FFU per well. The pre-mixing
was performed overnight at 4uC. Viral adsorption was allowed to
proceed for 3 hours at 37uC. An overlay medium containing 2.5%
fetal bovine serum and 0.8% methylcellulose in DMEM was
added at the conclusion of adsorption. The infected monolayer
was incubated at 37uC. After 72 to 120 hours of infection, the
overlay medium was removed from the wells, and the BHK cells
were washed with cold PBS. The cells were fixed for 15 min in
3.7% formaldehyde/PBS. After washing with PBS, the cells were
permeabilized with 0.1% Nonidet P40/PBS for 15 min and
blocked with 3% bovine serum albumin/PBS for 30 min. Infected
cells were detected by a monoclonal anti-dengue antibody (Ameri-
can Type Culture Collection, No. HB-114). The monoclonal anti-
dengueantibodyreactedwithallserotypesofthedenguevirus.After
washing with PBS, antibody-labeled cells were detected using a
secondary antibody conjugated to horseradish peroxidase. The
labeling was visualizedusing TMB.TheFFUwerecounted, and the
neutralizing antibody titer was calculated as the reciprocal of the
highest dilution that produced a 40% reduction of FFU compared
to control samples containing the virus and pre-immunization sera.
The neutralizing antibody titer was designated as 2
2 when
neutralizing antibody titer was less than 2
3.
Statistical analyses
Statistical analyses were carried using GraphPad Prism version
5.02 (GraphPad Software, Inc.). Statistical significance of differ-
ences between groups was assessed using a one-tailed Student’s t-
test. Differences with a P value of less than 0.05 were considered
statistically significant.
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